Domainex's Drug Discovery Pipeline

Domainex’s drug discovery programme includes epigenetics and inflammatory disease<br />

Domainex is a pharmaceutical contract manufacturing company that specializes in drug discovery. We have an excellent pedigree, delivering an average of one candidate every year for the past six years on behalf of our collaborators and clients Domainex has also utilized its expertise and proprietary technologies to develop its own internal pipeline – focussed on exciting and novel, but challenging drug targets.

Domainex's lead programme targets key kinases (TBK1/IKKe) involved in innate immunity, to develop new disease-modifying drugs against inflammatory indications such as rheumatoid athritis and lupus. Domainex has nominated a drug candidate (DMXD-011) which has proven to be efficacious in in vivo models.  We are now seeking partners interested in taking this to clinical studies.

Domainex has also focussed its capabilities on oncology drug discovery with the development of an epigenetics-targeted pipeline, namely against the protein methyl-transferases (PKMT). Domainex is a leader in PKMT drug discovery and is developing highly potent, selective and drug-like compounds.

Target Indication Target expression Assay Crystal Structure Hit ID H2L Lead Optimisation Candidate Nomination
TBK1/IKKε Inflammatory Disease (rheumatoid arthritis and lupus) Tick Tick Tick Tick Tick Tick DMXD-011
G9a Oncology Tick Tick Tick Tick Tick Tick  
SMYD3 Oncology Tick Tick   Tick Tick Tick  
EZH2   Tick Tick   Tick      
KMT target 4 Oncology Tick Tick   Tick      
KMT target 5 Oncology Tick Tick Tick